Literature DB >> 25167591

Schedules of controlled substances: rescheduling of hydrocodone combination products from schedule III to schedule II. Final rule.

.   

Abstract

With the issuance of this final rule, the Administrator of the Drug Enforcement Administration reschedules hydrocodone combination products from schedule III to schedule II of the Controlled Substances Act. This scheduling action is pursuant to the Controlled Substances Act which requires that such actions be made on the record after opportunity for a hearing through formal rulemaking. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule II controlled substances on persons who handle (manufacture, distribute, dispense, import, export, engage in research, conduct instructional activities with, conduct chemical analysis with, or possess) or propose to handle hydrocodone combination products.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25167591

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  48 in total

1.  Recreational marijuana legalization and prescription opioids received by Medicaid enrollees.

Authors:  Yuyan Shi; Di Liang; Yuhua Bao; Ruopeng An; Mark S Wallace; Igor Grant
Journal:  Drug Alcohol Depend       Date:  2018-10-25       Impact factor: 4.492

2.  Opioid Prescriptions in Older Medicare Beneficiaries After the 2014 Federal Rescheduling of Hydrocodone Products.

Authors:  Yong-Fang Kuo; Mukaila A Raji; Victor Liaw; Jacques Baillargeon; James S Goodwin
Journal:  J Am Geriatr Soc       Date:  2018-04-14       Impact factor: 5.562

Review 3.  Opioid Prescribing in an Opioid Crisis: What Basic Skills Should an Oncologist Have Regarding Opioid Therapy?

Authors:  Joseph Arthur; Akhila Reddy
Journal:  Curr Treat Options Oncol       Date:  2019-04-01

4.  Alcohol and Drug Use and Aberrant Drug-Related Behavior Among Patients on Chronic Opioid Therapy.

Authors:  Cynthia I Campbell; Andrea H Kline-Simon; Michael Von Korff; Kathleen W Saunders; Constance Weisner
Journal:  Subst Use Misuse       Date:  2017-03-27       Impact factor: 2.164

5.  Decline in opioid prescribing after federal rescheduling of hydrocodone products.

Authors:  Mukaila A Raji; Yong-Fang Kuo; Deepak Adhikari; Jacques Baillargeon; James S Goodwin
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-12-21       Impact factor: 2.890

6.  Change in prescription habits after federal rescheduling of hydrocodone combination products.

Authors:  Susan Seago; Adam Hayek; Jessica Pruszynski; Megan Greene Newman
Journal:  Proc (Bayl Univ Med Cent)       Date:  2016-07

7.  Association between cannabis laws and opioid prescriptions among privately insured adults in the US.

Authors:  Mukaila A Raji; N Ogechi Abara; Habeeb Salameh; Jordan R Westra; Yong-Fang Kuo
Journal:  Prev Med       Date:  2019-05-21       Impact factor: 4.018

8.  Drug Enforcement Agency 2014 Hydrocodone Rescheduling Rule and Opioid Dispensing after Surgery.

Authors:  Mark D Neuman; Sean Hennessy; Dylan S Small; Craig Newcomb; Lakisha Gaskins; Colleen M Brensinger; Duminda N Wijeysundera; Brian T Bateman; Hannah Wunsch
Journal:  Anesthesiology       Date:  2020-05       Impact factor: 7.892

9.  Evaluation of opioid use among patients with back disorders and arthritis.

Authors:  Corey J Hayes; Nalin Payakachat; Chenghui Li
Journal:  Qual Life Res       Date:  2018-07-23       Impact factor: 4.147

10.  Opioid Prescribing Trends in Women Following Mastectomy or Breast-Conserving Surgery Before and After the 2014 Federal Reclassification of Hydrocodone.

Authors:  Derrick C Gibson; Lin-Na Chou; Mukaila A Raji; Jacques G Baillargeon; Yong-Fang Kuo
Journal:  Oncologist       Date:  2019-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.